Search

Paul A Gurbel

from Baltimore, MD
Get Report
Also known as:
P A Gurbel
Phone and address:
7208 Bellona Ave, Baltimore, MD 21212
(410) 377-2364
Related to:
Dorothy R GurbelDoreen J YarbroughVictor Todd Yarbrough, 50Marina M Prezenchuk, 60Neal Aronson, 98Anne Y Gurbel, 67E S Yarbrough, 77Alfred Michael GurbelEdwin S YarbroughGerald A Hofkin, 88Sergey Prezenchuk
Connected to:
Walter T Gurbo, 78Nisha Gurbuxani, 42Huseyin Gurbuz, 57Muzaffer Gurbuz, 58Serdar Gurbuzer, 52Amina Gurcan, 39Bulent K Gurcan, 49Angela Gurchie, 41Andrea M Gurcsik, 45Gary S Gurcsik, 54

Paul Gurbel Phones & Addresses

  • 7208 Bellona Ave, Baltimore, MD 21212 (410) 377-2364
  • 108 Saint Albans Rd, Baltimore, MD 21212
  • 2411 Belvedere Ave, Baltimore, MD 21215
  • 7862 Church Neck Rd, Claiborne, MD 21624
  • Saint Michaels, MD
  • 8600 Liberty Rd, Randallstown, MD 21133
  • 8688 Liberty Rd, Randallstown, MD 21133
  • Durham, NC

Work

Company: Paul A Gurbel MD Address: 5051 Greenspring Ave Suite 304, Baltimore, MD 21209 Phones: (410) 601-9600

Education

School / High School: University of Maryland At Baltimore / Professional Schools 1983

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Cardiovascular Disease, 1989

Specialities

Cardiology • Interventional Cardiology

Professional Records

Medicine Doctors

Paul Gurbel Photo 1

Dr. Paul A Gurbel, Baltimore MD - MD (Doctor of Medicine)

View page
Specialties:
Cardiology
Interventional Cardiology
Address:
Paul A Gurbel MD
5051 Greenspring Ave Suite 304, Baltimore, MD 21209
(410) 601-9600 (Phone)
Certifications:
Cardiovascular Disease, 1989
Internal Medicine, 1986
Interventional Cardiology, 1999
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Paul A Gurbel MD
5051 Greenspring Ave Suite 304, Baltimore, MD 21209

Sinai Hospital of Baltimore
2401 West Belvedere Avenue, Baltimore, MD 21215
Education:
Medical School
University of Maryland At Baltimore / Professional Schools
Graduated: 1983
Medical School
Duke University Hospital
Graduated: 1983
Medical School
Johns Hopkins
Graduated: 1983
Paul Gurbel Photo 2

Paul A. Gurbel

View page
Specialties:
Cardiovascular Disease, Interventional Cardiology
Work:
Innova Cardiology
2328 W Joppa Rd, Baltimore, MD 21209
(410) 601-9600 (phone), (410) 367-2590 (fax)
Education:
Medical School
University of Maryland School of Medicine
Graduated: 1983
Procedures:
Angioplasty
Cardiac Catheterization
Cardioversion
Echocardiogram
Electrocardiogram (EKG or ECG)
Pacemaker and Defibrillator Procedures
Conditions:
Acute Myocardial Infarction (AMI)
Angina Pectoris
Ischemic Heart Disease
Abdominal Aortic Aneurysm
Abnormal Vaginal Bleeding
Languages:
English
Description:
Dr. Gurbel graduated from the University of Maryland School of Medicine in 1983. He works in Baltimore, MD and specializes in Cardiovascular Disease and Interventional Cardiology. Dr. Gurbel is affiliated with Sinai Hospital Of Baltimore.
Paul Gurbel Photo 3

Paul A Gurbel, Baltimore MD

View page
Specialties:
Cardiologist
Address:
2401 W Belvedere Ave, Baltimore, MD 21215
Education:
University of Maryland, School of Medicine - Doctor of Medicine
Johns Hopkins Hospital - Fellowship - Pulmonary Disease (Internal Medicine)
Duke University Hospital - Fellowship - Cardiology
Duke University Hospital - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
American Board of Internal Medicine Sub-certificate in Interventional Cardiology (Internal Medicine)

Resumes

Resumes

Paul Gurbel Photo 4

Paul Gurbel

View page
Work:
Lifebridge Health
Other
Lifebridge Health
Medical Doctor Faha

Business Records

Name / Title
Company / Classification
Phones & Addresses
Paul Gurbel
Md Faha
LifeBridge Health
Hospital & Health Care · General Hospital · Medical Doctor's Office
2401 W Belvedere Ave, Baltimore, MD 21215
2434 W Belvedere Ave, Baltimore, MD 21215
(410) 601-5653, (410) 367-0212, (410) 601-9355, (410) 601-8492
Paul Gurbel
Cardiovascular
Baltimore Heart Associates
Medical Doctor's Office
2401 W Belvedere Ave, Baltimore, MD 21215

Publications

Us Patents

Methods Of Inhibiting Platelet Activation With Selective Serotonin Reuptake Inhibitors

View page
US Patent:
6552014, Apr 22, 2003
Filed:
Mar 12, 2001
Appl. No.:
09/804689
Inventors:
Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Christopher M. OConnor - Durham NC
Assignee:
HeartDrug Research, L.L.C. - Ellicott City MD
International Classification:
A61K 3155
US Classification:
51421402, 514217, 51425213, 51425405, 51425407, 514315, 514438, 514653, 514656, 514657
Abstract:
The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.

Assessment Of Cardiac Health And Thrombotic Risk In A Patient

View page
US Patent:
7381536, Jun 3, 2008
Filed:
Mar 1, 2005
Appl. No.:
11/070845
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
C12Q 1/56
US Classification:
435 13
Abstract:
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

Assessment Of Cardiac Health And Thrombotic Risk In A Patient

View page
US Patent:
8058023, Nov 15, 2011
Filed:
Apr 8, 2008
Appl. No.:
12/099727
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
C12Q 1/56
US Classification:
435 13
Abstract:
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

Detection Of Restenosis Risk In Patients Receiving A Stent By Measuring The Characteristics Of Blood Clotting Including The Measurement Of Maximum Thrombin-Induced Clot Strength

View page
US Patent:
8070678, Dec 6, 2011
Filed:
Oct 4, 2006
Appl. No.:
11/663599
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
A61B 5/00
US Classification:
600369
Abstract:
A method of selecting a stent for implantation in the circulatory system of a human being includes the steps of determining a threshold level of platelet hyper-coaguability (PHC). One marker of PHC is platelet-fibrin mediated clot strength (MA) of blood. MA above a threshold demonstrates a risk of restenosis that is relatively high. In practicing the method, a sample of blood is obtained from a patient who requires implantation of a stent, the blood sample is tested for its platelet-fibrin mediated clot strength, the clot strength of the blood sample is compared with the threshold level; if the blood sample has a clot strength below the threshold level, selecting a bare metal stent, and if the blood sample has a clot strength at or above the threshold level, selecting a drug-eluting stent. The method includes, in a preferred embodiment, use of a viscoelastic monitor to perform the testing step. Other markers of PHC may also be employed such as measurement of thrombin generation and/or platelet reactivity.

Assessment Of Cardiac Health And Thrombotic Risk In A Patient

View page
US Patent:
8440420, May 14, 2013
Filed:
Nov 7, 2011
Appl. No.:
13/290377
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
C12Q 1/56
US Classification:
435 13, 435214, 435217
Abstract:
The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

Detection Of Restenosis Risk In Patients Receiving A Stent By Measuring The Characteristics Of Blood Clotting Including The Measurement Of Maximum Thrombin-Induced Clot Strength

View page
US Patent:
20120264150, Oct 18, 2012
Filed:
Dec 1, 2011
Appl. No.:
13/309121
Inventors:
Paul A. Gurbel - Baltimore MD, US
International Classification:
G01N 33/86
C12Q 1/56
US Classification:
435 13, 436 63
Abstract:
Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level. The determined platelet coagulability level of said blood sample is compared with a threshold level of blood platelet coagulability. A determined platelet coagulability level above said threshold level indicates that a risk of restenosis is relatively high. If the determined platelet coagulability level is below said threshold level, a bare metal stent is selected. If the determined platelet coagulability level is at or above said threshold level, a drug-eluting stent is selected.

Determining A Treatment Plan For Patients Undergoing Thrombotic Event By Monitoring P-Selectin

View page
US Patent:
62307134, May 15, 2001
Filed:
Jan 29, 1998
Appl. No.:
9/015385
Inventors:
Margaret R. Dalesandro - Devon PA
Paul A. Gurbel - Baltimore MD
Victor L. Serebruany - Ellicott City MD
International Classification:
A61B 1900
US Classification:
128898
Abstract:
A treatment plan for patients suffering from a thrombotic event can be determined by measuring membrane bound and/or soluble P-selectin. The degree of reperfusion can be determined by assessing the level of soluble P-selectin subsequent to reperfusion. Additionally, predicting whether thrombolytic therapy will induce reperfusion can be determined by measuring the level of membrane bound P-selectin prior to reperfusion.

Methods Of Inhibiting Platelet Activation With Selective Serotonin Reuptake Inhibitors

View page
US Patent:
62457829, Jun 12, 2001
Filed:
May 17, 1999
Appl. No.:
9/312987
Inventors:
Victor L. Serebruany - Ellicott City MD
Paul A. Gurbel - Baltimore MD
Christopher M. O'Connor - Durham NC
Assignee:
Heartdrug Research L.L.C. - Ellicott City MD
International Classification:
A61K 31445
A61K 3134
A61K 3115
A61K 31135
A61K 3103
US Classification:
514321
Abstract:
The present invention pertains to methods for reducing the platelet activation state in an individual comprising administering a selective serotonin reuptake inhibitor (SSRI). The platelet activation state is reduced upon administering a SSRI, as measured by one or more platelet activation markers. The invention also relates to methods for treating or preventing an individual at risk for a vascular event, disease or disorder by administering a SSRI.
Control profile
Paul A Gurbel from Baltimore, MD Get Report